Romania is becoming one of the most important emerging clinical trial markets in Europe. With a population of 19 million, more than 3,000 trials listed on ClinicalTrials.gov, 17 medical universities and a 30 day silent approval pathway, Romania gives sponsors access to a large patient base within the EU clinical trial framework.
The country is especially relevant for oncology, cardiovascular disease, neurology, endocrinology, diabetes, respiratory disease and infectious disease studies.
For sponsors, Romania is not only a lower cost geography. It is a growing EU research market with treatment naive patient pools, strong academic medical infrastructure and rising international CRO activity.